These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

511 related items for PubMed ID: 19492955

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Preparation of 0.05% FK506 suspension eyedrops and its pharmacokinetics after topical ocular administration.
    Yuan J, Zhai JJ, Chen JQ, Ye CT, Zhou SY.
    J Ocul Pharmacol Ther; 2009 Aug; 25(4):345-50. PubMed ID: 19492954
    [Abstract] [Full Text] [Related]

  • 23. Ocular pharmacokinetics of mapracorat, a novel, selective glucocorticoid receptor agonist, in rabbits and monkeys.
    Proksch JW, Lowe ER, Ward KW.
    Drug Metab Dispos; 2011 Jul; 39(7):1181-7. PubMed ID: 21441467
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Simultaneous quantification of gatifloxacin, moxifloxacin, and besifloxacin concentrations in cornea and aqueous humor by LC-QTOF/MS after topical ocular dosing.
    Domingos LC, Moreira MV, Keller KM, Viana FA, Melo MM, Soto-Blanco B.
    J Pharmacol Toxicol Methods; 2017 Jul; 83():87-93. PubMed ID: 27670369
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Ocular penetration and pharmacokinetics of topical clarithromycin eye drops to rabbits.
    Zhang J, Wang L, Zhou J, Zhang L, Xia H, Zhou T, Zhang H.
    J Ocul Pharmacol Ther; 2014 Feb; 30(1):42-8. PubMed ID: 24199739
    [Abstract] [Full Text] [Related]

  • 29. Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers.
    Torkildsen G, O'Brien TP.
    Clin Ther; 2008 Nov; 30(11):2005-14. PubMed ID: 19108788
    [Abstract] [Full Text] [Related]

  • 30. Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis.
    Sanders ME, Norcross EW, Moore QC, Shafiee A, Marquart ME.
    Cornea; 2009 Oct; 28(9):1055-60. PubMed ID: 19724203
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Besifloxacin ophthalmic suspension 0.6%.
    Carter NJ, Scott LJ.
    Drugs; 2010 Oct; 70(1):83-97. PubMed ID: 20030427
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Ocular pharmacokinetics comparison between 0.2% olopatadine and 0.77% olopatadine hydrochloride ophthalmic solutions administered to male New Zealand white rabbits.
    Iyer GR, Cason MM, Womble SW, Li G, Chastain JE.
    J Ocul Pharmacol Ther; 2015 May; 31(4):204-10. PubMed ID: 25775192
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Calculation of AQCmax: comparison of five ophthalmic fluoroquinolone solutions*.
    Fukuda M, Sasaki H.
    Curr Med Res Opin; 2008 Dec; 24(12):3479-86. PubMed ID: 19032129
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.